Manufacturing Centrient Pharmaceuticals doubles its statin production capacity with a...

Centrient Pharmaceuticals doubles its statin production capacity with a new manufacturing facility


Centrient Pharmaceuticals, a worldwide leader in antifungal agents, sustainable antibiotics, and statins, has announced that the manufacturing of statins at its new production facility has begun. The company’s statin manufacturing capacity will be boosted after the completion of its second specialized plant in Toansa, India. Centrient will be able to satisfy the increasing market demand of sustainably manufactured APIs such as Rosuvastatin and Atorvastatin.

Statins are the most commonly-used medications, used to treat heart diseases and high cholesterol, and they are also the best-selling drugs on the market. The continuous prevalence of high cholesterol problems across the world has resulted in a persistent increase in sales of Atorvastatin and Rosuvastatin, replacing previous generation statins from the market.

Centrient was established about a decade ago and has since evolved to become one of the world’s leading suppliers of statin APIs, serving significant pharmaceutical firms over the world.

Customers have supply reliability from the company’s specialized manufacturing plant, as well as impressive characteristics like prolonged shelf life and vast batch sizes. When compared to typical manufacturers, its catalytic mode of synthesis and patented technique reduces the use of toxic solvents, produces less pollution, and reduces the carbon output of the company by 32%.

The announcement of plant extension comes after the company achieved important statin milestones in recent years. Using the name DSM Sinochem Pharmaceutical, it was the first pharmaceutical firm to provide Atorvastatin API in 2012, with a certificate of Suitability to the European Pharmacopoeia’s Monograph (CEP). Its state-of-the-art plant in Toansa, India, has been producing distinctive Atorvastatin APIs for third-party consumers since 2014.

Furthermore, in 2016, the firm was among the first three pharmaceutical companies in the world to provide Generic APIs of Rosuvastatin under CEP. The final dosage formulations of generic Atorvastatin and Rosuvastatin were released in Western Europe after two years.

“We are extremely proud that we have been able to complete this project in a timely way given the challenges of executing such a complex project amid the COVID pandemic,” says Jim McPherson, Chief Quality & Technical Operations Officer.

Latest news

Zealand Pharma and Iktos collaborate to develop AI Technology for Peptide drug design

Specialists in artificial intelligence for new drug design, Iktos announced a research partnership with Zealand Pharma to...

UK’s NICE makes recommendation for Imlifidase by Hansa Biopharmaceutical

With the National Institute for Health and Care Excellence’s (NICE) recommendation for the use of imlifdase, over...

Heart failure drug by Cytokinetics delayed – FDA wants more time to review

The Food and Drug Administration requires more time to study Cytokinetics’ omecamtiv mecarbil following analysis of some...
- Advertisement -

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you